Some considerations in the design of substrate and tissue-specific inhibitors of monoamine oxidase.
D000818:Animals; D001665:Binding Sites; D001692:Biological Transport; D001921:Brain / Q000187:drug effects / Q000201:enzymology; D002490:Central Nervous System / Q000187:drug effects / Q000201:enzymology; D006321:Heart / Q000187:drug effects; D007700:Kinetics; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D008433:Mathematics; D008930:Mitochondria, Liver / Q000187:drug effects / Q000201:enzymology; D008995:Monoamine Oxidase / Q000378:metabolism; D008996:Monoamine Oxidase Inhibitors / Q000138:chemical synthesis; D009206:Myocardium / Q000201:enzymology; D010293:Pargyline / Q000031:analogs & derivatives / Q000139:chemically induced / Q000494:pharmacology; D010636:Phenols; D011485:Protein Binding; D051381:Rats; D012701:Serotonin / Q000378:metabolism; D013329:Structure-Activity Relationship; D013997:Time Factors; D014439:Tyramine
D008996:Monoamine Oxidase Inhibitors; D010636:Phenols; D012701:Serotonin; D010293:Pargyline; D008995:Monoamine Oxidase; D014439:Tyramine